Literature DB >> 33491917

Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.

Scott Ayton1, Stuart Portbury1, Pawel Kalinowski1, Puja Agarwal2, Ibrahima Diouf1,3, Julie A Schneider4, Martha Clare Morris2, Ashley I Bush1.   

Abstract

OBJECTIVE: This paper is a proposal for an update of the iron hypothesis of Alzheimer's disease (AD), based on large-scale emerging evidence.
BACKGROUND: Iron featured historically early in AD research efforts for its involvement in the amyloid and tau proteinopathies, APP processing, genetics, and one clinical trial, yet iron neurochemistry remains peripheral in mainstream AD research. Much of the effort investigating iron in AD has focused on the potential for iron to provoke the onset of disease, by promoting proteinopathy though increased protein expression, phosphorylation, and aggregation. NEW/UPDATED HYPOTHESIS: We provide new evidence from a large post mortem cohort that brain iron levels within the normal range were associated with accelerated ante mortem disease progression in cases with underlying proteinopathic neuropathology. These results corroborate recent findings that argue for an additional downstream role for iron as an effector of neurodegeneration, acting independently of tau or amyloid pathologies. We hypothesize that the level of tissue iron is a trait that dictates the probability of neurodegeneration in AD by ferroptosis, a regulated cell death pathway that is initiated by signals such as glutathione depletion and lipid peroxidation. MAJOR CHALLENGES FOR THE HYPOTHESIS: While clinical biomarkers of ferroptosis are still in discovery, the demonstration of additional ferroptotic correlates (genetic or biomarker derived) of disease progression is required to test this hypothesis. The genes implicated in familial AD are not known to influence ferroptosis, although recent reports on APP mutations and apolipoprotein E allele (APOE) have shown impact on cellular iron retention. Familial AD mutations will need to be tested for their impact on ferroptotic vulnerability. Ultimately, this hypothesis will be substantiated, or otherwise, by a clinical trial of an anti-ferroptotic/iron compound in AD patients. LINKAGE TO OTHER MAJOR THEORIES: Iron has historically been linked to the amyloid and tau proteinopathies of AD. Tau, APP, and apoE have been implicated in physiological iron homeostasis in the brain. Iron is biochemically the origin of most chemical radicals generated in biochemistry and thus closely associated with the oxidative stress theory of AD. Iron accumulation is also a well-established consequence of aging and inflammation, which are major theories of disease pathogenesis.
© 2021 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; cognitive decline; iron; neurodegeneration; pathology

Year:  2021        PMID: 33491917     DOI: 10.1002/alz.12282

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  18 in total

1.  Selective ferroptosis vulnerability due to familial Alzheimer's disease presenilin mutations.

Authors:  Mark A Greenough; Darius J R Lane; Rachelle Balez; Helena Targa Dias Anastacio; Zhiwen Zeng; Katherine Ganio; Christopher A McDevitt; Karla Acevedo; Abdel Ali Belaidi; Jari Koistinaho; Lezanne Ooi; Scott Ayton; Ashley I Bush
Journal:  Cell Death Differ       Date:  2022-04-21       Impact factor: 15.828

Review 2.  Tau Toxicity in Neurodegeneration.

Authors:  Shu-Yu Liang; Zuo-Teng Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2022-03-31       Impact factor: 5.682

Review 3.  The Role of Microglia in Alzheimer's Disease From the Perspective of Immune Inflammation and Iron Metabolism.

Authors:  Hui-Zhi Long; Zi-Wei Zhou; Yan Cheng; Hong-Yu Luo; Feng-Jiao Li; Shuo-Guo Xu; Li-Chen Gao
Journal:  Front Aging Neurosci       Date:  2022-06-30       Impact factor: 5.702

4.  Association Between Copper and Global Cognition and the Moderating Effect of Iron.

Authors:  Young Min Choe; Guk-Hee Suh; Boung Chul Lee; Ihn-Geun Choi; Jun Ho Lee; Hyun Soo Kim; Jee Wook Kim
Journal:  Front Aging Neurosci       Date:  2022-03-29       Impact factor: 5.750

Review 5.  Microglia and Astrocytes in Alzheimer's Disease in the Context of the Aberrant Copper Homeostasis Hypothesis.

Authors:  Amit Pal; Isha Rani; Anil Pawar; Mario Picozza; Mauro Rongioletti; Rosanna Squitti
Journal:  Biomolecules       Date:  2021-10-28

6.  Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation.

Authors:  Lin Li; Wen-Jun Li; Xiang-Ru Zheng; Qing-Long Liu; Qian Du; Yu-Jie Lai; Song-Qing Liu
Journal:  Mol Med       Date:  2022-01-29       Impact factor: 6.354

Review 7.  Iron Dyshomeostasis and Ferroptosis: A New Alzheimer's Disease Hypothesis?

Authors:  Feixue Wang; Jiandong Wang; Ying Shen; Hao Li; Wolf-Dieter Rausch; Xiaobo Huang
Journal:  Front Aging Neurosci       Date:  2022-03-22       Impact factor: 5.750

Review 8.  Ferroptosis and Its Potential Role in the Nervous System Diseases.

Authors:  Yiyang Zhou; Wei Lin; Tian Rao; Jinyu Zheng; Tianlei Zhang; Min Zhang; Zhenlang Lin
Journal:  J Inflamm Res       Date:  2022-03-03

9.  Forsythoside A Mitigates Alzheimer's-like Pathology by Inhibiting Ferroptosis-mediated Neuroinflammation via Nrf2/GPX4 Axis Activation.

Authors:  Chunyue Wang; Shanshan Chen; Hangyu Guo; Hongbo Jiang; Honghan Liu; Haoran Fu; Di Wang
Journal:  Int J Biol Sci       Date:  2022-02-28       Impact factor: 6.580

Review 10.  Regulatory miRNAs in Cardiovascular and Alzheimer's Disease: A Focus on Copper.

Authors:  Anna Sacco; Fabio Martelli; Amit Pal; Claudia Saraceno; Luisa Benussi; Roberta Ghidoni; Mauro Rongioletti; Rosanna Squitti
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.